{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:16Z","timestamp":1790270716988,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["PS3416"],"award-info":[{"award-number":["PS3416"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["RCCPDB-Nov21\/100008"],"award-info":[{"award-number":["RCCPDB-Nov21\/100008"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009253","name":"European Association for the Study of the Liver","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016338","name":"Imperial Experimental Cancer Medicine Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["MFAG 25697"],"award-info":[{"award-number":["MFAG 25697"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023178","name":"Cancer Treatment and Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023178","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jhepr.2023.100702","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T20:43:49Z","timestamp":1676666629000},"page":"100702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials"],"prefix":"10.1016","volume":"5","author":[{"given":"Claudia Angela Maria","family":"Fulgenzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4904-5133","authenticated-orcid":false,"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Korolewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8441-6470","authenticated-orcid":false,"given":"Charalampos-Vlasios","family":"Stikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Openshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-0578","authenticated-orcid":false,"given":"Marianna","family":"Silletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-532X","authenticated-orcid":false,"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1209-5735","authenticated-orcid":false,"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Scotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0103","authenticated-orcid":false,"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2023.100702_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhepr.2023.100702_bib2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2023.100702_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2023.100702_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100702_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib6","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100702_bib7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100702_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100702_bib9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jhepr.2023.100702_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evidence"},{"issue":"Suppl. 7","key":"10.1016\/j.jhepr.2023.100702_bib11","first-page":"S808","article-title":"Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. [Abstract LBA35]","volume":"33","author":"Qin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib12","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Suppl. 7","key":"10.1016\/j.jhepr.2023.100702_bib13","first-page":"S808","article-title":"Primary results\u00a0from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). [Abstract LBA34]","volume":"33","author":"Finn","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib14","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/S1470-2045(22)00497-1","article-title":"COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma","volume":"23","author":"Cabibbo","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib16","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jhepr.2023.100702_bib18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib\u00a0in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100702_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib20","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib21","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib22","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"Cainap","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib25","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.21.00163","article-title":"Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II\u2013III trial","volume":"39","author":"Qin","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl. 7","key":"10.1016\/j.jhepr.2023.100702_bib26","doi-asserted-by":"crossref","first-page":"S1402","DOI":"10.1016\/j.annonc.2022.08.033","article-title":"Final analysis of RATIONALE-301: randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma","volume":"33","author":"Qin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000515302","article-title":"Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: a network meta-analysis","volume":"10","author":"Vogel","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2023.100702_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2022.06.058","article-title":"Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network metanalysis of phase III trials","volume":"174","author":"Fulgenzi","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2023.100702_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib30","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/s41416-020-0805-y","article-title":"Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review","volume":"122","author":"Belin","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2023.100702_bib31","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jhep.2019.01.028","article-title":"Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival","volume":"70","author":"Llovet","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100702_bib32","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jamaoncol.2022.2666","article-title":"Log-rank test vs MaxCombo and difference in restricted mean survival time tests for comparing survival under nonproportional hazards in immuno-oncology trials: a systematic review and meta-analysis","volume":"8","author":"Mukhopadhyay","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2023.100702_bib33","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child\u2013Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100702_bib34","article-title":"Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study","volume":"8","author":"Fessas","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jhepr.2023.100702_bib35","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2023.100702_bib36","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1136\/gutjnl-2021-326259","article-title":"CXCR2 inhibition enables NASH-HCC immunotherapy","volume":"71","author":"Leslie","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2023.100702_bib37","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2023.100702_bib38","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jhepr.2023.100702_bib39","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J\u00a0Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923000332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923000332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:06:43Z","timestamp":1778904403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555923000332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2589555923000332"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100702","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100702"}}